Hematologist
CION Cancer Clinics
Ruxolitinib in myelofibrosis: what it does and does not do | CION Cancer Clinics
Ruxolitinib is a daily JAK inhibitor tablet that shrinks an enlarged spleen and eases night sweats, itching, tiredness and weight loss for many people with myelofibrosis. It does not remove the disease or reliably reverse the marrow scarring. Haemoglobin and platelets often dip early, so blood tests are frequent. Generic versions are sold in India, and scheme cover varies. Here is what to expect. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does ruxolitinib do in myelofibrosis?
- What can ruxolitinib do, and what can it not?
- What happens before and after you start ruxolitinib?
- Which side effects should you watch for?
- Who does ruxolitinib not suit, and how do people access it in India?
- What do families often misunderstand about ruxolitinib?
- Common questions about ruxolitinib
The short answer
What does ruxolitinib do in myelofibrosis?
Ruxolitinib is a daily tablet that shrinks an enlarged spleen and eases symptoms such as night sweats, itching, tiredness and weight loss in many people with myelofibrosis. It does not remove the disease or reliably reverse the marrow scarring, and it can lower haemoglobin and platelets, so it needs close monitoring.
How it works
It belongs to a group of medicines called JAK inhibitors. In myelofibrosis, a signalling pathway called JAK-STAT is switched on too strongly, whatever gene change started the disease. Ruxolitinib turns that signal down. This calms the overactive blood-making cells and the inflammation they drive, which is where much of the spleen growth and many symptoms come from.
Who it is usually offered to
It is most often used for people with a troublesome spleen or whole-body symptoms, particularly in the intermediate and high risk groups. Someone in a low risk group with few symptoms may not need it at all. It does not require a JAK2 gene change to work; people with CALR or MPL changes can benefit too.
Generic names only
This page uses the generic name. Several makers sell it in India under different brand names. The medicine inside is the same molecule, and this page does not compare brands or suggest where to buy it.
Honest expectations
What can ruxolitinib do, and what can it not?
What it often does
What it does not do
Shrinks the spleen, easing fullness and left-sided ache
Remove myelofibrosis from the marrow
Eases night sweats, itching and bone pain
Reliably reverse the scarring
Helps many people regain appetite and weight
Correct low haemoglobin, which may fall at first
Improves energy and daily activity for many
Replace a transplant for those who may need one
Works across JAK2, CALR and MPL types
Work for everyone, or keep working forever
Not sure whether this applies to you?
Ask an oncologistStarting treatment
What happens before and after you start ruxolitinib?
-
Checks before the first tablet
A full blood count, kidney and liver tests, and screening for hepatitis B and tuberculosis. Both infections are common in India and can flare when the immune system is dampened. Tell your team about any past TB, jaundice or shingles.
-
Your dose is set by your team
The starting dose depends mainly on your platelet count and kidney and liver function. It is different for different people, so never compare doses with anyone else.
-
Frequent blood tests at first
Haemoglobin and platelets often dip in the early months. Blood counts are checked often during this period, and the dose may be adjusted. This dip is expected and usually settles.
-
Feeling the benefit
Symptoms such as sweats and itching often ease early. The spleen shrinks more gradually. Your doctor examines it at each visit, and an ultrasound may be repeated to compare its size with the start. Appetite and weight often improve as the pressure on the stomach eases.
-
Ongoing review
Once stable, visits are spaced out. Your team watches for infections, falling counts, skin changes and signs the medicine is losing effect. Keep a simple diary of symptoms, weight and any infections between visits, and bring it with your latest blood reports.
Side effects
Which side effects should you watch for?
Most people manage well with monitoring. These are the effects your team looks out for, and what you can notice at home.
Lower blood counts
The commonest effect. Low haemoglobin brings tiredness and breathlessness; low platelets bring bruising or bleeding.
Tell your team about
- New bruises or bleeding gums
- Breathlessness getting worse
Infections
Shingles, urine and chest infections are more likely. Rarely, tuberculosis or hepatitis B can reactivate.
Tell your team about
- A painful blistering rash
- Fever, cough or burning urine
Weight and cholesterol
Many people regain weight, which is often welcome after months of eating little. Cholesterol can rise, so it may be checked, especially if you already have diabetes or heart disease.
Skin, dizziness and headache
Some people get dizziness or headaches. Certain skin cancers are seen more often, so show your doctor any new or changing spot.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being straight with you
Who does ruxolitinib not suit, and how do people access it in India?
It may not suit people with very low platelets, active untreated infections, or severe kidney or liver problems, though doses can sometimes be adapted. For people whose main problem is low haemoglobin rather than the spleen, other approaches may come first. Where a transplant is realistic, the tablet may be used to prepare for it, not instead of it.
When it stops working
The benefit can fade over time. Other JAK inhibitors exist, such as fedratinib, pacritinib and momelotinib, but their availability in India varies. Ask your haematologist what can actually be obtained, and whether a clinical trial is an option.
Cost and support
It is taken long term, so cost matters. Generic versions have made it more affordable in India, but prices differ widely. Coverage under Aarogyasri, PM-JAY, CGHS, ECHS, EHS or cashless insurance depends on your scheme and whether home tablets are included. Rules change, so check your current entitlement. Some makers run patient support programmes; ask your team. CION's haematology team can help you understand your options but does not supply any particular brand.
Never stop, skip or change your dose on your own. Stopping suddenly can bring symptoms and the spleen back quickly. Your treating team decides every change.Commonly believed
What do families often misunderstand about ruxolitinib?
"The spleen is smaller, so the disease has gone."
A smaller spleen shows the tablet is working on symptoms. The disease is still in the marrow. Stopping on that belief can bring symptoms back fast.
"Haemoglobin fell, so the medicine is harming him."
An early dip in haemoglobin is expected and usually settles. Your team may adjust the dose or support haemoglobin. This is a conversation to have with them, not a reason to stop.
"A cheaper brand must be weaker."
Approved generics contain the same molecule. Price reflects the maker, not a different medicine. Any switch should still be told to your team so they can watch your counts.
"Ayurvedic tablets alongside it can only help."
Some herbal products change how the body handles ruxolitinib or affect the liver. Show every remedy, and every new prescription from another doctor, to your haematology team first.
Did you know
Some common antibiotics and antifungal medicines can raise the level of ruxolitinib in the blood. Carry a list of your medicines and show it to any doctor, dentist or pharmacist who prescribes something new.
Questions we are asked
Common questions about ruxolitinib
How long will I need to take ruxolitinib?
Usually for as long as it keeps helping and side effects stay manageable, which for many people is years. It controls symptoms rather than removing the disease, so it is not a fixed course. Your haematologist reviews at each visit whether it is still the right medicine for you.
What if I miss a tablet?
Do not take extra to make up for it. Follow the written instructions your team gave you, and ask them what to do if you are unsure. If you miss several doses, for example while travelling or unwell, tell your team, because symptoms can return quickly.
Can I take ruxolitinib if my platelets are low?
Sometimes, at an adapted dose with close blood tests. Very low platelets may make it unsuitable, and your team may consider another JAK inhibitor designed for that situation, if it can be obtained. This decision depends on your repeat counts, not one result.
Is it chemotherapy?
No. It is a targeted tablet that blocks a specific signal. It does not usually cause hair loss or the sickness people link with chemotherapy. It does lower blood counts and raise infection risk, so it still needs careful monitoring by a haematologist.
Will it help my low haemoglobin?
Usually not directly, and haemoglobin often dips early on. Some people see it steady later as symptoms improve. Low haemoglobin is often managed alongside with transfusions or other medicines. Momelotinib may help haemoglobin in some people, where available.
Can I get vaccines while on it?
Most inactivated vaccines, such as flu and pneumonia vaccines, are generally encouraged. Live vaccines usually need caution. The shingles vaccine type matters. Ask your haematologist before any vaccine, and ideally plan vaccines before starting.
Does Aarogyasri or insurance cover it?
It depends on the scheme and policy. Some cover oral cancer tablets taken at home; others cover only hospital care. Check with Aarogyasri, PM-JAY, CGHS, ECHS, EHS or your insurer, as rules change. Our team can help you ask the right questions.
Can I be treated with it at CION?
CION's haematology team can review your reports, explain whether a JAK inhibitor fits your situation, and monitor you on treatment. Your prescription and any brand choice are decided with your treating haematologist. Bring every report and a list of all your medicines.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Ruxolitinib Phosphate
- Leukemia & Lymphoma Society — Myelofibrosis
- National Cancer Institute — Chronic Myeloproliferative Neoplasms Treatment (PDQ) - Patient Version
- Blood Cancer UK — Understanding blood cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Massive Splenomegaly: Living With an Enlarged SpleenOther ways the spleen is managedLow haemoglobin in myelofibrosis and how it is managedWhen haemoglobin dips on treatmentMyelofibrosis Treatment Cost in IndiaPlanning for long-term tablet costsDIPSS Risk Scoring in MyelofibrosisHow risk group shapes when it is started
Talk to us
Wondering whether this tablet fits your situation?
Send us your blood counts, spleen scans and current medicines. Our haematology team will explain the options and what to ask. One helpline serves every CION centre.